Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Digitalis grandiflora extract is a botanical extract derived from the aerial parts and roots of the *Digitalis grandiflora* Miller plant, commonly known as yellow foxglove. The extract contains a variety of bioactive secondary metabolites, most notably cardiac glycosides (cardenolides), which are known to inhibit the sodium-potassium pump (Na+/K+-ATPase). Research conducted at Hacettepe University has demonstrated that the extract possesses potent and selective cytotoxic activity against several human cancer cell lines, including HeLa (cervical cancer), HepG2 (hepatocellular carcinoma), and HEp-2 (laryngeal cancer). Notably, the extract shows significantly lower toxicity toward noncancerous cell lines, such as 3Y1 rat fibroblasts, suggesting potential for development as a targeted antineoplastic agent with a favorable therapeutic index.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Digitalis grandiflora extract.